Condition (MeSH)
Fibrous Dysplasia of Bone
ClinicalTrials.gov lists 34 trials for Fibrous Dysplasia of Bone or a narrower condition beneath it. National Institute of Dental and Craniofacial Research (NIDCR) has the most among industry and government lead sponsors, with 9.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
24 of the 34 trials are tagged with Fibrous Dysplasia of Bone itself; the rest are tagged with a narrower condition beneath it.
When did Fibrous Dysplasia of Bone trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 1 |
| 2016 | 2 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Fibrous Dysplasia of Bone trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 6 |
| Observational | 16 |
How many Fibrous Dysplasia of Bone trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Active, not recruiting | 2 |
| Completed | 23 |
| Withdrawn | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Fibrous Dysplasia of Bone trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Dental and Craniofacial Research (NIDCR) | 9 |
| AstraZeneca | 2 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
Which drugs are being tested for Fibrous Dysplasia of Bone? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DENOSUMAB | 2 |
| FULVESTRANT | 1 |
| Anastrozole | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| BLOOD SAMPLE | 2 |
| No Interventions | 1 |
| 18F-NaF PET/CT | 1 |
| Letrozol (Femara, Novartis) | 1 |
| Denosumab 120 Mg/1.7 Ml Inj | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Fibrous Dysplasia of Bone trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hospitalisation | 2 | 1 |
| Appendicitis | 1 | 1 |
| Arthralgia | 1 | 1 |
| Bone Pain | 1 | 1 |
| Bronchitis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Fibrous Dysplasia of Bone? (22)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Phenotyping Pain in Patients With Fibrous Dysplasia/McCune-Albright Syndrome. | The Journal of clinical endocrinology and metabolism | 2024 | Yes |
| RANKL inhibition reduces lesional cellularity and Gα<sub>s</sub> variant expression and enables osteogenic maturation in fibrous dysplasia. | Bone research | 2024 | Yes |
| Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone. | The New England journal of medicine | 2023 | Yes |
| Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial. | Bone | 2022 | Yes |
| A Signature of Circulating miRNAs Associated With Fibrous Dysplasia of Bone: the mirDys Study. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 2020 | Yes |
Showing 5 of 22 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Fibrous dysplasia of bone | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Fibrous dysplasia of bone | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Fibrous dysplasia of bone | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Fibrous dysplasia of bone | 249 | Exact | Orphadata Science knowledge files, Product 1 |
| Fibrous dysplasia of bone | 249 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.